• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AVELUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • AVELUMAB chembl:CHEMBL3833373 ApprovedAntineoplastic

    Alternate Names:

    MSB0010682
    MSB-0010682
    MSB0010718C
    BAVENCIO
    AVELUMAB

    Drug Info:

    FDA Approval Merkel cell carcinoma
    Drug Class Therapeutic Antibodies
    (4 More Sources)

    Publications:

    Aguiar et al., 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data., Immunotherapy
    Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget
    Hamid O et al., 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma., N Engl J Med
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
  • AVELUMAB   CD274

    Interaction Score: 23.19

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Programmed cell death 1 ligand 1 other
    Direct Interaction yes

    PMIDs:
    28472902 26918451 23724846


    Sources:
    MyCancerGenome ChemblInteractions CIViC PharmGKB TTD FDA

  • AVELUMAB   EGFR

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31086949


    Sources:
    CIViC

  • MyCancerGenome: AVELUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    BAVENCIO Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Merkel cell carcinoma

    Publications:

  • CIViC: AVELUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget
    Aguiar et al., 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data., Immunotherapy

  • TTD: Bavencio

    • Version: 2020.06.01

    Alternate Names:
    D0W8HN TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Avelumab

    • Version: 2020.06.01

    Alternate Names:
    D0K7SX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3833373

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: avelumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3833373

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Avelumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21